Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Dr Adam Brufsky Describes the Evolution of Treatment Options for HER2-Low Breast Cancer
December 8th 2022Human epidermal growth factor receptor 2 (HER2)-low breast disease has a number of new treatments available, and more providers need to be aware of how it differs from other forms of breast cancer, according to Adam Brufsky, MD, PhD, University of Pittsburgh, at the San Antonio Breast Cancer Symposium.
Read More
Dr Jose P. Leone Highlights the Importance of Breast Cancer Awareness for Male Patients
December 8th 2022Jose P. Leone, MD, director of the program for breast cancer in men at the Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, shares why patients and providers need to pay more attention to how breast cancer impacts male patients.
Read More
Dr Dawn Hershman Discusses Tactics to Increase Drug Adherence in Clinical Trials
December 7th 2022Dawn L. Hershman, MD, an oncologist from Columbia University, shared insight into the current challenge of ensuring drug adherence within clinical trials and how this adherence can impact the quality of care for patients in real-world settings.
Read More
Dr Irene Kang Shares Cognitive Impairment Results From the RxPonder Breast Cancer Study
December 7th 2022Irene M. Kang, MD, from City of Hope, shared some of the results from her analysis of cognitive impairment in women with breast cancer who participated in the RxPonder study, which assessed which patients would benefit most from chemotherapy.
Read More
Dr Neil Iyengar Previews SABCS Presentation on Metabolic Dysregulation in Breast Cancer
December 5th 2022Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).
Read More
Stem Cell Transplant May Be Viable Treatment for Patients With HIV, Leukemia, Says Dr Jana Dickter
November 16th 2022Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.
Read More
Dr Michel Michaelides Speaks About Implications of Gene Therapy Study Results in Ophthalmology
October 27th 2022The results of a study showing improved functional vision and retinal sensitivity have implications for gene therapy in ophthalmological conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Read More
Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer
October 7th 2022Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Dr Rona Silkiss Details the Use of Biologics to Treat Thyroid Eye Disease
October 4th 2022At the American Academy of Ophthalmology's annual conference, Rona Z. Silkiss, MD, FACS, an oculoplastic surgeon and owner of Silkiss Eye Surgery, dived into how biologic therapies can be used to treat thyroid eye disease and what can be done to ensure patients have access to these treatments.
Read More
Dr Michael Cohen Contrasts the Manifestation and Treatment of Wet vs Dry AMD
October 4th 2022Michael N. Cohen, MD, a retinal surgeon at Wills Eye Hospital and Mid Atlantic Retina, describes the differences between wet and dry age-related macular degeneration (AMD) and how gene therapy could help treat the condition in the future.
Read More
Dr Richard Allen Speaks on the Evolution of Oculoplastic Surgery for Children
October 3rd 2022Richard C. Allen, MD, PhD, FACS, an oculoplastic surgeon at Texas Children's Hospital and a professor at Baylor College of Medicine, spoke on how oculoplastic surgery in pediatric patients has changed at the American Academy of Ophthalmology's 2022 conference.
Read More
Dr Michael Chiang Chronicles the NEI's Research Into AI, Telemedicine in Ophthalmology
October 2nd 2022Advances in imaging and data science are changing the nature of retina practice, and retina specialists need to stay on top of these, said Michael F. Chiang, MD, director of the National Eye Institute (NEI), who also discussed some of the current research the agency is conducting into artificial intelligence (AI) and telemedicine.
Read More
Dr Michel Michaelides Dives Into How Gene Therapy Can Treat Retinitis Pigmentosa
October 2nd 2022Gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and there is likely to be an increase in approved gene therapies for ophthalmic conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Read More
Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient
September 29th 2022Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
Dr William Oh Discusses Goals of Prostate Cancer Awareness Month
September 26th 2022William Oh, MD, chief medical officer at Sema4 and a clinical professor of medicine at Mount Sinai, discusses Prostate Cancer Awareness Month and possible reasons for disparities in diagnoses and mortality in prostate cancer.
Read More
Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions
September 16th 2022Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal
September 14th 2022Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Read More
How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says
September 5th 2022Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory
September 2nd 2022Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Read More
Medicines for Europe: Off-Patent Medicines Could Strengthen Europe’s Health Systems
July 21st 2022During its annual conference in Spain, Medicines for Europe shared recommendations for greater use of off-patent medications, such as biosimilars and generics, as a way ensure medicines remain available to patients in light of global events and supply chain issues.
Read More
Most Patients Received Inadequate Information on Switching to Biosimilars, Survey Finds
July 12th 2022A survey of patients with breast cancer and oncologists found that when switching to a trastuzumab biosimilar from the reference product (Herceptin), many patients were not given adequate information on what biosimilars are and their benefits.
Read More
Lessons Learned in New Orleans Can Be Shared Across the US, Powell Says
July 12th 2022This the third installment of a series of interviews on Takeda’s partnership with Xavier University of Louisiana (T-REX), Takeda's Lauren Powell, MPA, PhD, discussed the impact Louisiana's hospital system has had on her work and the need for the pharmaceutical industry to invest in more partnerships like T-REX.
Read More
Dr Lauren Powell: Takeda’s Partnership With Xavier Is a Long-term Investment
July 8th 2022In the second interview in a series, Takeda’s Lauren Powell, MPA, PhD, vice president, US Health Equity & Community Wellness, discussed how a partnership with Xavier University of Louisiana will unfold over several years.
Read More
Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access
July 2nd 2022Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Read More